key: cord-0799814-1vr8r4qj authors: Khan, Atif; Rao, T. Subba; Joshi, Hiren M. title: Phage therapy in the Covid-19 era: Advantages over antibiotics date: 2022-02-16 journal: Curr Res Microb Sci DOI: 10.1016/j.crmicr.2022.100115 sha: 9af6ca3ca514c3e5621aa9d52ffdfb216a8b15c1 doc_id: 799814 cord_uid: 1vr8r4qj Today, the entire world is battling to contain the spread of COVID-19. Massive efforts are being made to find a therapeutic solution in the shortest possible time. However, the research community is becoming increasingly concerned about taking a shortsighted strategy without contemplating the long-term consequences. For example, It has been reported that only 8.4% of total COVID-19 patients develop a secondary bacterial infection. In comparison, 74.6% of them are administered with antibiotics as prophylactic treatment. We contend that overuse of broad-spectrum antibiotics increases the likelihood of AMR development and negatively affects the patient's recovery due to the prevalence of the "gut-lung axis.". Consequently, the use of antibiotics to treat COVID-19 patients must be rationalized, or an alternative treatment must be sought that does not risk contributing to AMR development and positively impacts the treatment outcomes. Phage therapy, a century-old concept, is one of the most promising approaches that can be adapted to serve this purpose. This review emphasizes the negative impact of excessive antibiotic use in COVID-19 treatment and provides an overview of how phage therapy can be used as an alternative treatment option. We have argued that targeted killing (narrow spectrum) and anti-inflammatory (which can target the primary cause of mortality in COVID-19) properties of phages can be an effective alternative to antibiotics. Over the last 2000 years, the human race has faced a number of epidemics/pandemics that have Despite the recent pandemic of Severe acute respiratory syndrome (SARS), we do not have a universal therapeutic agent or any promising drug candidate against these severe acute respiratory syndrome (except antibody cocktails and recently developed drugs like Paxlovid and Molnupiravir ) that can be quickly deployed to treat prevailing SARS-CoV-2 infection (Dolgin, 2021) . The current pandemic was caused by SARS-CoV-2, which first appeared in the Chinese province of Hubei in November 2019 and spread throughout the world over the next few months . The SARS-CoV-2 virus is highly contagious and spreads through human-tohuman contact. The respiratory system is the primary site of infection for the virus. However, growing evidence suggests that multiple organs, including the heart, brain, kidney, and digestive system/organ, are involved (Gavriatopoulou et al., 2020; Peiris et al., 2021) . The adaptive immune system plays a critical role in combating viral attacks on our bodies by producing neutralizing antibodies against viral antigens. However, the adaptive immune system's response weakens with age or any other physiological infirmity, causing a delay in the production of antiviral antibodies. (Weyand and Goronzy, 2016) . In the case of SARS-CoV-2 infection, any delay in activation of adaptive immune response results in an aggressive inflammatory response by the innate immune system (inflammatory cytokine storm). This inflammatory response has the potential to cause severe lung damage and subsequent secondary bacterial infection. As a result, prescribing antibiotics in addition to standard antiviral therapy as a prophylactic measure to prevent secondary bacterial infections is being adopted around the world. (Beović et al., 2020; Grau et al., 2021; Yacouba et al., 2021) . However, a meta-analysis found that only 8.4 % of COVID-19 patients were diagnosed with a secondary bacterial infection. On the contrary, 74.6 % of patients are given antibiotics as a preventative measure to avoid secondary infection (Langford et al., 2021) . This scenario suggests that antibiotics are being used inappropriately and possibly excessively in COVID treatment, which may result in a significant increase in antibiotic-resistant organisms in a short period of time (Founou et al., 2021; Livermore, 2021) . Antibiotic resistance is already predicted to become a pandemic by 2050, causing 10 million deaths per year worldwide. Antibiotic overuse in the COVID-19 pandemic may hasten this predicted scenario (Tagliabue and Rappuoli, 2018 ). In addition, antibiotics have several indirect effects on our immune system. For example, antibiotics mediated extensive killing of gut microbiota (i.e. dysbiosis) is known to have a negative impact on immune homeostasis (Becattini et al., 2016; Sun et al., 2019) . Therefore, it is highly desirable to have calibrated approach for antibiotics usage or find alternative therapeutics for infection management. The new therapeutic(s) should be free from the associated danger of resistance development and have properties that synergistically or positively impact our immune system. In addition to the direct impact of antibiotic usage during COVID-19 on AMR development, there are many indirect effects one needs to keep in mind before prescribing antibiotics. should seek out an effective alternative therapy to replace or supplement antibiotics. Bacteriophages are viruses that specifically kill their bacterial hosts. They are also known as Furthermore, like antibiotics, bacteriophages provide the flexibility to treat bacterial infections with a single phage or a mixture of multiple phages (i.e. phage cocktail) to eradicate polymicrobial infection. Inflammation is a hallmark of severe SARS-CoV-2 infection, manifested by increased inflammatory biomarkers such as C reactive proteins (CRP), lactic dehydrogenase (LDH), ferritin, D-dimer, IL-6, and others, resulting in a cytokine storm (García, 2020) . Interestingly, the most promising aspect of phage therapy is its anti-inflammatory properties. Miedzybrodzki et al. Though phage therapy is one of the most promising technologies for combating antibioticresistant infections, many obstacles must be overcome before being used as a routine therapeutic agent. For example, there is a lack of reliable data on clinical trials and regulatory guidelines for phage-based therapeutics (Liu et al., 2021) . This disparity in efficacy within the test group is primarily due to our limited understanding of in vivo pharmacokinetics and pharmacodynamics of bacteriophages (Nilsson, 2019) . Furthermore, the immunogenicity of a given phage must be thoroughly evaluated prior to application in order to avoid immunogenic clearance of phages (Loc-Carrillo and Abedon, 2011). The Phage's narrow specificity limits its applicability to a single strain of an organism. As a result, multiple phages must be screened to identify that strainspecific Phage. However, there are multiple phages specific to strain of interest and, therefore, can be easily isolated from the environment. Other critical aspects that need to be considered before selecting a phage for treatment include phage resistance and the lysogenic life cycle of a given phage (Berryhill et al., 2021) . Even though phage therapy has few limitations, given the rapid rise in antibiotic resistance and the limited supply of new antibiotics, we must embrace this technology to combat bacterial infection. Data from various ongoing clinical trials and active research in various laboratories will assist us in overcoming those limitations. Additionally, we urgently need to change our perception of this century-old technology, and many more research laboratories must contribute to its rapid deployment as anti-infection therapy. The COVID-19 pandemic has presented us with numerous challenges, and the entire world is striving to overcome this situation at the earliest. The rapid development of vaccines in record time has given us hope that we will be able to overcome this pandemic soon. However, we must also consider the long-term consequences of this pandemic and plan accordingly. Excessive use of antibiotics during this pandemic is one of the major concerns shown by the research community. Today, clinicians across the world are prescribing antibiotics to prevent secondary bacterial infection in Covid-19 patients. However, data suggest that most of the time, this prophylactic use of antibiotics is not justified. On the contrary, this excessive usage has significantly increased the possibilities of the accelerated emergence of antibiotic-resistant organisms. As a result, we must recalibrate our approach towards treating the patient with antibiotics and increase our efforts to develop an alternative infection control strategy. Phage therapy having numerous success stories can be an ideal alternative.The rapid expansion of antibiotic production during World War II has 15 completely diverted our attention from this century-old technology. Now the time has come to bring it back as an alternative to antibiotics. Bacteriophages with high specificity (targeted killing) and anti-inflammatory properties will be of great value to treat a disease like Covid-19. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Bacteriophage adhering to mucus provide a non-host-derived immunity Antibiotic-Induced Changes in the Intestinal Microbiota and Disease Role of the microbiota in immunity and inflammation Antibiotic use in patients with COVID-19: a 'snapshot' Infectious Diseases International Research Initiative (ID-IRI) survey Evaluating the potential efficacy and limitations of a phage for joint antibiotic and phage therapy of Staphylococcus aureus infections Host receptors for bacteriophage adsorption Risk Factors and Outcomes of Hospitalized Patients With Severe Coronavirus Disease 2019 (COVID-19) and Secondary Bloodstream Infections: A Multicenter Case-Control Study Microbiota-Driven Tonic Interferon Signals in Lung Stromal Cells Protect from Influenza Virus Infection Pleiotropy complicates a trade-off between phage resistance and antibiotic resistance Phages as immunomodulators and their promising use as anti-inflammatory agents in a cftr loss-of-function zebrafish model Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa Bacteriophage therapy for infections in CF Phage therapy for respiratory infections Modulation of Gut Microbiota for the Prevention and Treatment of COVID-19 Broadscale phage therapy is unlikely to select for widespread evolution of bacterial resistance to virus infection Broadscale phage therapy is unlikely to select for widespread evolution of bacterial resistance to virus infection COVID-19, antibiotics and One Health: a UK environmental risk assessment Antimicrobial Use in COVID-19 Patients in the First Phase of the SARS-CoV-2 Pandemic: A Scoping Review Microbes, metabolites, and the gut-lung axis Gut microbiota and Covid-19-possible link and implications The race for antiviral drugs to beat COVID -and the next pandemic The Perfect Bacteriophage for Therapeutic Applications-A Quick Guide Phages for Biofilm Removal The COVID-19 pandemic: a threat to antimicrobial resistance containment Immune Response, Inflammation, and the Clinical Spectrum of COVID-19 Organ-specific manifestations of COVID-19 infection Perspectives of Phage Therapy in Nonbacterial Bacteriophage Interactions With Epithelial Cells: Therapeutic Implications. Front Bacteriophages and transplantation tolerance Phage Therapy: Combating Infections with Potential for Evolving from Merely a Treatment for Complications to Targeting Diseases Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic Phage-Antibiotic Synergy Is Driven by a Unique Combination of Antibacterial Mechanism of Action and Stoichiometry Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis The respiratory tract microbiome and lung inflammation: a two-way street A more appropriate use of antibiotics in COVID-19 infection Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria Pulmonary-intestinal cross-talk in mucosal inflammatory disease Variability in digestive and respiratory tract Ace2 expression is associated with the microbiome Antidrug resistance in the Indian ambient waters of Ahmedabad during the COVID-19 pandemic Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis Dysbiosis and the immune system The microbiome and autoimmunity: a paradigm from the gut-liver axis The Safety and Toxicity of Phage Therapy: A Review of Animal and Clinical Studies Antibiotic resistance during and beyond COVID-19 Pros and cons of phage therapy. Bacteriophage 1, 111 Population cycles and species diversity in dynamic Killthe-Winner model of microbial ecosystems A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses T4 Phage Tail Adhesin Gp12 Counteracts LPS-Induced Inflammation In Vivo Mechanisms of Antibiotic Resistance Pharmacological limitations of phage therapy Antipseudomonal Bacteriophage Reduces Infective Burden and Inflammatory Response in Murine Lung Pathological findings in organs and tissues of patients with COVID-19: A systematic review T4 bacteriophage-mediated inhibition of adsorption and replication of human adenovirus in vitro Cytokine Storm; What We Know So Far 11 Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell Antiviral Therapy. Viral Pathog Urban wastewater treatment plants as hotspots for antibiotic resistant bacteria and genes spread into the environment: a review The landscape of antibiotic resistance The microbial metabolite desaminotyrosine protects from influenza through type I interferon Bacteriophage Therapy Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic: An interrupted time series analysis Antibiotic-Induced Disruption of Gut Microbiota Alters Local Metabolomes and Immune Responses 9 Marine viruses -major players in the global ecosystem How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections Changing Priorities in Vaccinology: Antibiotic Resistance Moving to the Top Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications Interactions between Bacteriophage, Bacteria, and the Mammalian Immune System A century of bacteriophage research and applications: impacts on biotechnology, health, ecology and the economy! Aging of the Immune System. Mechanisms and Therapeutic Targets A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens Bacteriophages Could Be a Potential Game Changer in the Trajectory of Coronavirus Disease (COVID-19) Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients Repurposing of antibiotics for clinical management of COVID-19: a narrative review The human microbiome and COVID-19: A systematic review The human microbiome and COVID-19: A systematic review Origin and Evolution of the 2019 Novel Coronavirus Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization Table 1: Comparative advantages of bacteriophages over antibiotics for infection control Antibiotics Bacteriophages Specificity to bacteria Non-specific, Non-target organisms, including normal flora of the body, gets killed.Highly specific for its bacterial host and does not disturb beneficial bacteria. Broad-spectrum antibiotics are repeatedly used to treat various infections and therefore, more chances of resistance development.Phage specificity limits the use of specific phage and therefore, limited chances of resistance development The shorter life ( outside host) and nonavailability of a host lead to rapid elimination from the environment.